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Abstract
Background: In order to control the spread of rubella and reduce the risk for congenital rubella syndrome, an
additional rubella vaccination program was set up for all secondary school students since 2008 in Zhejiang, China.
Methods: We conducted a descriptive analysis of rubella incidence among different age groups from 2005 to 2015 and
a serosurvey of female subjects aged 15–39 years to understand the possible effects of this immunization program.
Results: The average annual rubella incidence rate had decreased from 15.86 per 100,000 population (2005–2007) to 0.75
per 100,000 population (2013–2015) in Zhejiang. The decrease in the rate of rubella incidence in girls aged 15–19 years
was more accelerated (from 138.30 to 0.34 per 100,000) than in the total population during 2008–2015 (from 32.20 to 0.
46 per 100,000). Of 1225 female subjects in the serosurvey, 256 (20.9%) were not immune to rubella. The proportion of
subjects immune to rubella was significantly different among different age groups (Wald χ2 = 22.19, p = 0.000), and
subjects aged 15–19 years old had the highest immunity (88.0%). Rubella antibody levels were significantly lower in
women aged 25–30 years with 26.7% of them not immune, followed by the group aged
20–24 years (25.0%) and 30–35 years (24.5%).
Conclusions: Rubella vaccine included in the Expanded Program on Immunization together with vaccination activities for
secondary school students can help in rubella control, particularly in targeted age groups in the program. Seroprevalence
of antibodies to the rubella virus amongst the female population within childbearing age in Zhejiang, China, is still too
low to provide immunity. In addition to vaccination programs in the secondary schools, rubella vaccination should also
be encouraged in women of childbearing age, which can be done effectively combined with pre-marital examination in
China.
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Background
Rubella, primarily a childhood disease, is generally benign
and asymptomatic [1]. It is reported that up to a half of
rubella infection may be subclinical or unapparent [2].
Rubella can result in some detrimental results including
miscarriage, fetal death, and congenital rubella syndrome
(CRS) when infection with the virus occurs in early
pregnancy, particularly during the first 16 weeks among
non-immunized women [3, 4]. Fortunately, rubella is a
vaccine-preventable disease, and the rubella-containing
vaccine (RCV) has demonstrated high safety and good
effectiveness. Considering the heavy burden of CRS, RCV
is recommended in the national children immunization
schedules by the World Health Organization [5].
Zhejiang province is a developed province in eastern
China. RCV was introduced for children in Zhejiang
since 1994, but recipients had to pay for the vaccine
until 2007. The rubella vaccine coverage in children was
less than 50% in Zhejiang as many other places in China
from 1994 to 2007 [6, 7]. RCV was included into the
Expanded Program on Immunization (EPI) at the end of
2007, and the vaccine was administered free of charge to
children at 8 months and 18–24 months of age. The
reported coverage rate of rubella was more than 90% in* Correspondence: hhqcdc@126.com
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children with mandatory vaccination through the EPI
after 2008.
However, the reported incidence rate reached the
highest level in 2007 (39.43 per 100,000 population) after
rubella was included in the diseases surveillance system
in China in 2004 [8]. Many studies have shown that the
children vaccination program with RCV may cause the
disease to spread to susceptible adults [9, 10]. Consider-
ing the increasing risk of CRS, the government of the
Zhejiang province set up an additional vaccination
campaign for Measles and Rubella Combined Attenu-
ated Live Vaccine (MR) covering all secondary school
students irrespective of immunization status since 2008
[11]. This program has shown significant effects toward
measles elimination in the Zhejiang province [12], but to
what extent it can contribute to rubella control and CRS
prevention are unclear yet. Meanwhile, understanding
the level of immunity towards rubella in women of
childbearing age is also critical to evaluate CRS risk and
to provide evidence for implementing further efforts. In
the present study, we hypothesize that the vaccination
program in secondary school students might be helpful
for rubella control, especially in those aged 15–19 years,
which was the target age group of this program. We
concurrently conducted a descriptive analysis of rubella
incidence among different age groups and seropreva-
lence survey in women 15–39 years of age to explore




The study was approved by the ethics committee of the
Zhejiang Provincial Center for Disease Control and
Prevention and was conducted in accordance with the
Good Clinical Practice guidelines and Declaration of
Helsinki. Written informed consent was obtained from
all participants or guardians of children (<18 years old)
prior to study entry.
Sources of rubella surveillance information
We collected the data on the annual rubella incidence
and age distribution of cases from the National Notifi-
able Diseases Reporting System (NNDRS) in Zhejiang
from 1 January 2005 to 31 December 2015. Information
on immunization strategies were obtained from the
routine EPI system from the Zhejiang Provincial Center
for Diseases Control and Prevention, China.
Seroprevalence survey
A multistage design was employed to obtain samples
from two counties of the Zhejiang Province from July to
September 2015, after geographical and economic
statuses were considered. Participants were stratified by
age into five groups: 15–19 years, 20–14 years, 25–29
years, 30–35 years, and 35–39 years. Sera were excluded
from individuals known to be affected by an acute infec-
tion, and at least 50 samples were required from each
age group in each county. After ethical approval was ob-
tained, each participant was sent a letter explaining the
aims of the project and asking for informed consent.
Participants were required to provide a 3 mL sample of
the venous blood.
Laboratory test
Serum samples were stored at −70 °C before test.
Serological tests were performed at the Measles &
Rubella Laboratory in the Zhejiang Provincial Center
for Diseases Control and Prevention, which met the
Accreditation Criteria for WHO National Measles &
Rubella Laboratories. The commercial enzyme-linked
immunosorbent assay (ELISA) kit for Rubella (SER-
ION ELISA classic anti-rubella virus IgG, Institute
Virion\Serion SDF.FA) was used to measure the level
of specific IgG antibodies against rubella virus in the
sera. Cut-off and final results were based on the
qualitative criteria outlined by the manufacturer, and
standard controls in duplicate and negative controls
were used in every plate. Seropositivity was defined as
a titer of >20 International Units (IU/mL) according to
the manufacturer’s guidance.
Statistical analysis
Incidence and proportion of rubella cases in target sub-
jects (15–19 years) of the immunization program in
secondary school students were analyzed for evaluating
the epidemiological effects. Seroprevalence of rubella
was calculated for subjects in our serosurvey, with 95%
confidence intervals (95% CI). Geometric mean concen-
trations (GMCs) were calculated using log-transformed
titers and were reported as back transformed titers. In
order to obtain an unbiased GMC, values below the
detection threshold (2 IU/mL) were assigned half of the
threshold value (1 IU/mL). A logistic regression model
and Wald χ2 test were used to assess the significance of
positive seroprevalence proportion between different
groups. Kruskal-Wallis H test was used to compare the
GMCs among groups.
All statistical analyses were performed using SPSS
version 20.0 (Statistical Product and Service Solutions,
developed by IBM corporation) and a two-tailed p value
<0.05 was considered statistically significant.
Results
Epidemiological effects on the total population
According to NNDRS, the average annual rubella inci-
dence rate had decreased from 15.86 per 100,000
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population (2005–2007, before introduction of RCV in
EPI) to 0.75 per 100,000 population (2013–2015) in the
Zhejiang province. The highest incidence of rubella was
37.87 per 100,000 in 2008, with the highest age specific
rate of 160.42 per 100,000 in the 15–19 years age group.
After implementing the vaccination campaign of MR in
secondary school students at the end of 2008, the pro-
portion of rubella cases in target subjects (15–19 years)
decreased from 34.5% in 2005 to 4.3% in 2015. Similarly,
the incidence rate of rubella in the 15–19 years age
group decreased to 0.35 per 100,000 in 2015, and the
rate was lower than that of the total population (0.50 per
100,000). Meanwhile, the ratio of rubella incidences in
the 15–19 years age group as compared to that of the
total population was also decreased from 4.50 in 2005 to
0.76 in 2015. As we can see from Fig. 1, the largest pro-
portion of rubella cases was in the 20–29 years age
group at 42.81% in 2015, while this rate was less than
1% before 2008.
Epidemiological effects for females
We can observe in Fig. 2 that the different age specific
rubella incidence in women was decreased and follows
that of the total population after 2008. The drop rate in
the 15–19 age group was faster than in total women,
and a lower incidence rate was found in this age group
compared with other groups since 2014 (0.34 per
100,000 in the 15–19 years age group vs. 0.46 per
100,000 in the total population, 2015). Conversely, the
incidence of rubella in the 20–39 year old women was
lower than that of other groups before 2007, and the
slow decrease in the incidence rate in this group caused
it to later have a higher rate than that of the total popu-
lation (0.95 per 100,000 in age group 20–39 years, 2015).
Immunity effects in females
A total of 1225 female subjects of 15 to 39 years old
were enrolled in this study (Table 1). The overall sero-
positivity rate for rubella was 79.1% (95% CI: 76.8–
81.4%), with a GMC of 38.5 IU/mL (95% CI: 35.5–
41.7 IU/mL). Fig. 3 shows the seropositivity rates and
GMC levels of rubella IgG antibodies by age group. The
proportion of subjects immune to rubella differed sig-
nificantly among different age groups (Wald χ2 = 22.19,
p = 0.000). For all participants, a U-curve distribution of
seropositive rates was found among different age groups.
Rubella antibody levels were significantly lower in
women aged 25–30 years with 26.7% of them not
immune, followed by those in age groups 20–24 years
(25.0%) and 30–35 years (24.5%). Subjects aged 15–19
years old had the highest immunity (88.0%) against
rubella, and the seropositive rate was decreased with age
until 30 years. The GMC among age groups generally
followed the trend of seropositivity and declined obvi-
ously from the highest level of 48.6 IU/mL at 15–19
years of age to a lower level of 30.0 IU/mL at 25–29
years of age. There was no significant difference in
GMCs among different age groups (χ 2 = 3.77, p = 0.439).
As we can see from Table 2, the lowest immunity to
rubella was found in the 25–29 years age group, with a
seropositivity rate of 73.3%. Women who were 25–29
years old had an odds ratio (OR) of 2.67 (95% CI: 1.66–
4.27) for non-immunity to rubella, compared with those
in the 15–19 years age group. Both 20–24 years group
and 30–34 years age group had seropositivity rates lower
than 80%, with OR of 2.44 (95% CI: 1.52–3.93) and 2.26
(95% CI: 1.39–3.67), respectively, for non-immunity to
rubella as compared with the 15–19 years age group.
Discussion
Rubella remains endemic in China and is an important
cause of severe birth defects through CRS [13, 14]. RCV
was not included in the Chinese EPI until 2007. Low
coverage rate of RCV in children persisted since its
introduction in Zhejiang in 1994. Even after including it
in the national EPI, RCV was only recommended for
children of ages 0–14 years. High incidence and increas-
ing proportion of rubella cases in adults in 2008 was a
warning that introducing a RCV program in childhood
may paradoxically increase the proportion of girls reach-
ing puberty who are susceptible to rubella [15]. An add-
itional RCV program covering all secondary school
students was set up in Zhejiang since 2008, to expedite
rubella control and reduce the risk of CRS. We per-
formed a descriptive analysis of rubella cases from 2005
to 2015 and a seroprevalence survey of women aged 15–
39 years to understand the effects of this program, espe-
cially in those target subjects aged 15–19 years.
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Fig. 1 Proportions of Rubella Cases by Age in Zhejiang, 2005–2015
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Our study showed that both the incidence and propor-
tion of rubella cases in target subjects (15–19 years) de-
creased after implementing the immunization campaign
of MR in secondary school students since 2008. Mean-
while, the ratio of rubella incidences in the 15–19 years
age group also decreased from 4.50 in 2005 to 0.76 in
2015 as compared to that of the total population. In
addition, we found that subjects aged 15–19 years had
the highest immunity (88.0%) and GMC antibody level
against rubella. This was mainly caused by the vaccin-
ation program with the MR vaccine in secondary school
students, similar to its effect on the improvement of
measles immunity [11]. Currently, most students in sec-
ondary schools do not have an immunization history
with RCV; thus, the vaccination program can improve
the rubella antibody level for protection in these age
groups [16]. The rapidly decreasing incidence and higher
immunity for rubella in the 15–19 years age group indi-
cated that the vaccination program in secondary school
students may expedite rubella control in target subjects.
In consideration of the high disease burden of CRS,
rubella prevention should be implemented among ado-
lescent girls and women of childbearing age. Some coun-
tries set up the rubella vaccination program only for
young women; however, this strategy had proved to be
ineffective for preventing the spread of rubella. A sup-
plementary vaccination for male adults was recom-
mended to achieve rubella elimination after an outbreak
in Japan [17]. Therefore, we called for a vaccination pro-
gram in secondary schools covering both male and fe-
male students [18]. It is more convenient to conduct an
immunization program in students when they are still
under the mandatory education system of China. In
addition, combination measles-rubella vaccines should
be encouraged in the vaccination programs. The most
important goal of public health is the elimination of
measles together with rubella. The measles elimination
program is already one of the most prioritized infectious
diseases elimination programs in China; rubella and CRS
prevention programs may benefit from the established
measles control campaigns [19]. Previous studies showed
that adults are becoming an important target of measles
in China [11, 20], highlighting that the combined vaccine
should be considered as a practical policy option. There-
fore, a vaccination program with a combination vaccine
may be the optimal choice to enhance immunity both
for measles and for rubella [11].
Despite the decrease in the incidence of rubella after
RCV was included in the EPI (<1 per 100,000 since
2014) in Zhejiang, this study demonstrated that more
Fig. 2 Incidence of Rubella among female population
Table 1 Demographic characteristics of paricipants included in




N Percent(%) N Percent(%) N Percent(%)
15y- 115 19.20 135 21.57 250 20.41
20y- 139 23.21 117 18.69 256 20.90
25y- 126 21.04 129 20.61 255 20.82
30y- 116 19.37 122 19.49 238 19.43
35-39y 103 17.20 123 19.65 226 18.45
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Fig. 3 The age-specific seropositivity rate and GMC against rubella
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than one in five women aged 15–39 years were not
immune to rubella. This immunity level is not enough
for effective control of rubella in a population [21], and
the rate is similar to that reported in other eastern prov-
inces of China [19]. A study from Germany showed that
the seropositivity for the rubella antibody was estimated
at 89.3% and 86.0% among boys and girls, respectively
[22]. Low rubella immunity in pregnant women has also
been reported in Canada [23].
Our results point toward a potential risk of CRS
according to the increasing proportion of rubella cases
in women within the conventional childbearing age
range of 20–39 years. There were 42.81% cases in the
age group of 20–29 years in 2015, while this rate was
less than 10% before the 2008. The incidence rate of ru-
bella in 20–39 year old women was higher than that of
the total population in 2015. The highest susceptibility
to rubella was found in women aged 25–29 years, with
almost one-third of them being not immune. The lower
immunity to rubella was also observed in women aged
20–24 years and 30–34 years. When compared with the
15–19 years age group, the ORs of those non-immune
to rubella was 2.67 (95% CI: 1.66–4.27) in the 25–29
years age group. Most of these subjects were born in an
era when rubella vaccine was just introduced in China,
and there was lack of naturally acquired immunity for
protection during their childhood due to lower preva-
lence of rubella [7, 9]. Therefore, rubella IgG levels were
usually lower in these subjects than in those born before
the introduction of the rubella vaccine [24, 25]. Mean-
while, most of them were not vaccinated with the rubella
vaccine because of the low coverage rate during that
period. Those women aged 20–35 years who were in the
most probable period for childbearing in China, had a
higher risk of rubella, which required attention for CRS
prevention. However, the current immunization program
cannot cover these age groups, and the long-term effects
of the vaccination campaign in secondary school
students are still unclear. The lower immunity to rubella
among 20–35-year-old women also indicates that a
targeted vaccination effort for adults is required, but it
will be very difficult to implement a campaign targeting
adults in China. In order to reduce the possible risk of
CRS, physicians should encourage rubella vaccination in
women of childbearing age. The test for antibody levels
against the rubella virus was included in the national
free pre-marital health checkup for all women of child-
bearing age in China and free rubella vaccination should
also be administered to those women who test negative
for the antibody to rubella during the examination.
Our study has some Limitations. This study has a
cross-sectional design and the method involves only an
indirect measure of trend. Additionally, the unavailability
of reliable vaccination records of adults restricted the
options for a more detailed analysis to investigate the
associations on immunity. Further studies are needed to
track the seroprevalence for rubella and to assess the
long-term protective efficacy of vaccination programs in
secondary school students.
Conclusions
Our findings indicated that vaccination programs using
RCV in secondary school students can curb the spread
of rubella and may reduce the risk of CRS. However,
seroprevalence of antibodies to rubella amongst the fe-
male population within child bearing age in Zhejiang,
China, is still too low to provide immunity. We strongly
suggest that in addition to implementing vaccination
programs in secondary schools, rubella vaccination
should also be encouraged in women of childbearing
age, which can be carried out effectively when combined
with the pre-marital examination in China.
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Table 2 Odds Ratios for Non immunity to Rubella between age
groups in female population
Age groups Seropositive rate (%) p OR (95%CI)
15y- 88.00 - -
20y- 75.00 0.000 2.44 (1.52–3.93)
25y- 73.33 0.000 2.67 (1.66–4.27)
30y- 76.47 0.001 2.26 (1.39–3.67)
35-39y 83.19 0.135 1.48 (0.88–2.49)
Note:“-”reference groups
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